

CITATION REPORT

List of articles citing

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases

DOI: 10.1016/j.clinthera.2008.08.008
Clinical Therapeutics, 2008, 30, 1426-47.

Source: <https://exaly.com/paper-pdf/44103637/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
305	Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. 2009 , 7, 263-274		53
304	A Review of the Impact of Lapatinib on Health-Related Quality of Life in the Management of Advanced solid Tumors. 2009 , 1, CMT.S3410		
303	Lapatinib in the management of breast cancer. 2009 , 6, 553-568		
302	ON-III inhibits erbB-2 tyrosine kinase receptor signal pathway and triggers apoptosis through induction of Bim in breast cancer cells. 2009 , 8, 739-43		17
301	New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. 2009 , 18 Suppl 3, S10-7		17
300	Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. 2009 , 135, 1137-48		34
299	Renal toxicity of targeted therapies. 2009 , 4, 121-33		41
298	Combining systemic therapies with radiation in breast cancer. 2009 , 35, 409-16		10
297	Targeting the DNA damage response in cancer. 2009 , 109, 2929-50		114
296	In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates. 2009 , 188, 98-103		23
295	Clinical pharmacokinetics of tyrosine kinase inhibitors. 2009 , 35, 692-706		316
294	ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. 2009 , 48, 3600-9		27
293	The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. 2009 , 14, 320-68		838
292	Targeted endoscopic imaging. 2009 , 19, 283-98		22
291	Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. 2009 , 11, 1185-93		26
290	A Syk inhibitor for sick platelets?. 2009 , 113, 3133-4		1
289	The VWD2B saga continues to Montreal. 2009 , 113, 3134-5		2

288	Lapatinib as a chemotherapeutic drug. 2009 , 4, 216-26	1
287	Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. 2009 , 15, 758-76	51
286	Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. 2010 , 16, 1396-409	9
285	Anticancer therapy induced cardiotoxicity: review of the literature. 2010 , 21, 578-90	59
284	Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. 2010 , 18, 113-8	31
283	Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. 2010 , 8, 437-47	153
282	Lapatinib, an Anticancer Kinase Inhibitor. 2010 , 465-492	
281	Selectively nonselective kinase inhibition: striking the right balance. 2010 , 53, 1413-37	247
280	Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents. 2010 , 128, 82-90	10
279	Molecular alterations in uterine serous carcinoma. 2010 , 116, 286-9	26
278	Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells. 2010 , 101, 2220-6	8
277	H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. 2010 , 29, 5193-203	85
276	. 2010 ,	25
275	Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. 2010 , 13	2
274	Lapatinib: new opportunities for management of breast cancer. 2010 , 2, 79-91	7
273	Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. 2010 , 70, 2256-63	100
272	X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. 2010 , 9, 1432-42	54
271	Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. 2010 , 16, 912-23	47

270	Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. 2010 , 19, 875-87	19
269	Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. 2010 , 78, 693-703	88
268	Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. 2010 , 28, 3562-9	192
267	Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib. 2010 , 40, 999-1013	14
266	Novel agents in the management of lung cancer. 2010 , 17, 4291-325	16
265	Reverse phase protein microarrays advance to use in clinical trials. 2010 , 4, 461-81	112
264	mTOR Pathway and mTOR Inhibitors in Cancer Therapy. 2010 ,	2
263	Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib. 2011 , 39, 1022-30	42
262	Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. 2011 , 50, 371-403	80
261	Moving towards dose individualization of tyrosine kinase inhibitors. 2011 , 37, 251-60	82
260	Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. 2011 , 37, 456-64	55
259	HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. 2011 , 307, 72-79	40
258	ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas. 2011 , 32, 841-7	18
257	Les cancers du sein HER2 : que devons-nous retenir dans notre pratique clinique quotidienne ?. 2011 , 98, 154-163	4
256	Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. 2011 , 20, 158-72	128
255	Modulation of P-gp expression by lapatinib. 2011 , 29, 1284-93	13
254	Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses. 2011 , 26, 1-8	39
253	Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer. 2011 , 1, 420-8	33

252	Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation. 2011 , 78, 195-205	21
251	Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. 2011 , 71, 1871-82	149
250	Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer. 2011 , 5, 1-14	9
249	The art of prescribing trastuzumab for HER2-positive breast cancer. 2011 , 3, 16-26	
248	The molecular biology and novel treatments of vestibular schwannomas. 2011 , 115, 906-14	48
247	Identification of potent EGFR inhibitors from TCM Database@Taiwan. 2011 , 7, e1002189	78
246	Lapatinib for advanced or metastatic breast cancer. 2012 , 17, 536-42	41
245	Personalized therapy in endometrial cancer: challenges and opportunities. 2012 , 13, 1-13	52
244	Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea. 2012 , 13, 1269-75	26
243	The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. 2012 , 8, 596	85
242	Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer. 2012 , 109, 21058-63	28
241	Cancer du sein. 2012 ,	
240	Small Molecule Tyrosine Kinase Inhibitors: The New Dawn for Cancer Therapy. 2012 , 9, 84-125	2
239	Future of targeted agents in metastatic colorectal cancer. 2012 , 1,	11
238	Treatment of vestibular schwannoma cells with ErbB inhibitors. 2012 , 33, 244-57	12
237	Primary systemic therapy in HER2-amplified breast cancer: a clinical review. 2012 , 12, 1005-13	10
236	Array-based pharmacogenomics of molecular-targeted therapies in oncology. 2012 , 12, 185-96	11
235	Cancer and age: general considerations. 2012 , 28, 1-18	51

234	Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles. 2012 , 23, 435101	11
233	Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents. 2012 , 39, 247-60	11
232	Hepatotoxicity associated with lapatinib in an experimental rat model. 2012 , 48, 279-85	6
231	Targeting the EGFR signaling pathway in cancer therapy. 2012 , 16, 15-31	512
230	Target therapy in elderly breast cancer patients. 2012 , 83, 422-31	5
229	[Tumor resistance to HER2 inhibitors: the drug sedimentation concept]. 2012 , 99, 665-72	1
228	Membrane progesterone receptor alpha as a potential prognostic biomarker for breast cancer survival: a retrospective study. 2012 , 7, e35198	22
227	Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and	3
226	An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. 2012 , 403, 1685-95	65
225	Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. 2012 , 14, 94-101	24
224	Allosteric modulation by protein kinase C leads to modified responses of EGF receptor towards tyrosine kinase inhibitors. 2012 , 24, 422-434	4
223	Stem cell microRNAs in senescence and immortalization: novel players in cancer therapy. 2013 , 33, 112-38	13
222	Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy. 2013 ,	5
221	Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy. 2013 , 8, 1736-49	12
220	Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation. 2013 , 31, 1458-65	22
219	The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. 2013 , 12, 134	50
218	Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and anti-tumor effect in breast cancer. 2013 , 8, 1429-42	27
217	Design and evaluation of radiolabeled tracers for tumor imaging. 2013 , 60, 365-83	10

216	Reverse Phase Protein Microarray Technology: Advances into the Clinical Research Arena. 2013 , 349-361	
215	Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer. 2013 , 69, 833-41	19
214	Diagnostic-Therapeutic Combinations. 2013 , 798-819	
213	The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse. 2013 , 138, 509-17	27
212	Oncogenic ERBB3 mutations in human cancers. 2013 , 23, 603-17	277
211	Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib. 2013 , 114, 2643-53	33
210	Development and validation of a high-performance liquid chromatography ultraviolet method for lapatinib quantification in human plasma. 2013 , 35, 796-802	12
209	Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. 2013 , 35, 562-87	63
208	Mechanisms of TKI-induced diarrhea in cancer patients. 2013 , 7, 162-7	36
207	Tosylate salts of the anticancer drug lapatinib. 2013 , 69, 1516-23	4
206	Targeted therapies in the treatment of advanced hepatocellular carcinoma. 2013 , 7, 87-102	18
205	Targeted therapy in HER2-positive breast cancer. 2013 , 1, 499-505	39
204	Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib. 2014 , 7, 245-51	5
203	Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies. 2014 , 14, 1229-42	6
202	Assay of lapatinib in murine models of cigarette smoke carcinogenesis. 2014 , 35, 2300-7	13
201	Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab. 2014 , 15, 365-70	5
200	Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer. 2014 , 23, 1637-54	4
199	Development of the rat model of lapatinib-induced diarrhoea. 2014 , 2014, 194185	9

198	EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship. 2014 , 23, 33-8	22
197	Taxanes in combination with biologic agents for ovarian and breast cancers. 2014 , 25, 536-54	2
196	Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man. 2014 , 44, 1083-98	3
195	Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. 2014 , 148, 197-209	6
194	Lapatinib. 2014 , 201, 125-43	12
193	Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. 2014 , 32, 145-53	21
192	Exploring inhibitory potential of Curcumin against various cancer targets by in silico virtual screening. 2014 , 6, 13-24	16
191	Small Molecules in Oncology. 2014 ,	3
190	Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug. 2014 , 461, 478-88	29
189	Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. 2014 , 103, 3810-3833	25
188	Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. 2014 , 15, e315-26	156
187	Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates. 2014 , 87, 631-42	17
186	Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer. 2014 , 32, 946-54	10
185	Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis. 2014 , 3, 236	4
184	Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism. 2014 , 35, 846-52	22
183	Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer. 2014 , 42, 822-30	15
182	Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation. 2015 , 106, 1429-37	28
181	Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. 2015 , 5, 16750	21

180	Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization. 2015 , 43, 449-57	10
179	Targeted Cancer Therapy: The Next Generation of Cancer Treatment. 2015 , 12, 3-20	282
178	Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation. 2015 , 6, 23383-98	25
177	The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. 2015 , 484, 16-28	35
176	Development and Validation of Rapid Stability-Indicating RP-HPLC-DAD Method for the Quantification of Lapatinib and Mass Spectrometry Analysis of Degraded Products. 2015 , 53, 932-9	8
175	Antimalarial activity of kinase inhibitor, nilotinib, in vitro and in vivo. 2015 , 68, 469-72	3
174	Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity. 2015 , 102, 115-31	19
173	Pharmacokinetic interaction study combining lapatinib with vorinostat in rats. 2015 , 95, 160-5	2
172	Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling. 2015 , 9, 2	14
171	Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer. 2015 , 6, 8481	79
170	Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer. 2015 , 136, 817-27	34
169	Trastuzumab is not a tyrosine kinase inhibitor. 2015 , 12, 669	3
168	Mechanisms of lapatinib resistance in HER2-driven breast cancer. 2015 , 41, 877-83	85
167	ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis. 2015 , 41, 646-52	38
166	Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors. 2015 , 26, 3946-53	89
165	HER2 as a therapeutic target in head and neck squamous cell carcinoma. 2015 , 21, 526-33	54
164	Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation. 2015 , 20, 1009-1017	31
163	Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression. 2016 , 7, 500-11	19

162	Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. 2016 , 56, 1484-1499	57
161	Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance. 2016 , 14, 503-7	8
160	Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients. 2016 , 90, 232-8	12
159	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. 2016 , 108,	18
158	Characterization of the binding of an anticancer drug, lapatinib to human serum albumin. 2016 , 160, 229-39	22
157	Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer. 2016 , 111, 577-591	26
156	Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. 2016 , 59, 10030-10066	77
155	Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. 2016 , 39, 396-406	21
154	Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence. 2016 , 37, 120-142	23
153	Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis. 2016 , 37, 2285-97	10
152	Liposomal formulation for co-delivery of paclitaxel and lapatinib, preparation, characterization and optimization. 2016 , 26, 175-87	22
151	Impact of germline and somatic missense variations on drug binding sites. 2017 , 17, 128-136	6
150	Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting. 2017 , 23, 350-378	15
149	Myofibroblasts have an impact on expression, dimerization and signaling of different ErbB receptors in OSCC cells. 2017 , 37, 25-37	2
148	A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids. 2017 , 25, 2901-2916	10
147	Synthesis and in vitro biological evaluation of novel quinazoline derivatives. 2017 , 27, 1584-1587	23
146	UPLC-ESI-MS/MS study of the effect of green tea extract on the oral bioavailability of erlotinib and lapatinib in rats: Potential risk of pharmacokinetic interaction. 2017 , 1049-1050, 30-40	17
145	A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. 2017 , 19, 54	17

144	Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. 2017 , 138, 689-697	19
143	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. 2017 , 8, 14864	78
142	Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials. 2017 , 73, 1209-1217	7
141	Quinazoline-1-deoxyojirimycin hybrids as high active dual inhibitors of EGFR and α -glucosidase. 2017 , 27, 4309-4313	21
140	Resistance to Targeted Therapies in Breast Cancer. 2017 ,	
139	EGFR Resistance. 2017 , 103-116	
138	In vitro and in vivo evaluation of paclitaxel-lapatinib-loaded F127 pluronic micelles. 2017 , 43, 390-398	13
137	Targeted therapy of brain metastases: latest evidence and clinical implications. 2017 , 9, 781-796	26
136	Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma. 2017 , 8, 2141-2152	14
135	ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases. 2017 , 2017, 1532534	7
134	Yes1 signaling mediates the resistance to Trastuzumab/Lapatinib in breast cancer. 2017 , 12, e0171356	18
133	Lapatinib nano-delivery systems: a promising future for breast cancer treatment. 2018 , 15, 495-507	21
132	Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2. 2018 , 111, 569-586	18
131	A pharmacokinetic study on lapatinib in type 2 diabetic rats. 2018 , 70, 191-195	2
130	CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer. 2018 , 14, 327-337	35
129	Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2-positive breast cancer. 2018 , 18, 958-964	1
128	High-resolution mapping of cancer cell networks using co-functional interactions. 2018 , 14, e8594	32
127	Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells. 2018 , 505, 187-193	12

126	Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect. 2018 , 439, 113-130	6
125	Synthesis and antitumor activity of novel 6,7,8-trimethoxy N-aryl-substituted-4-aminoquinazoline derivatives. 2018 , 28, 2561-2565	7
124	Predicting Cancer Drug Response using a Recommender System. 2018 , 34, 3907-3914	57
123	Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity. 2018 , 503, 677-683	3
122	Lapatinib. 2018 , 211, 19-44	41
121	Amino alcohols and their respective 2-phenyl-N-alkyl aziridines as potential DNA minor groove binders. 2018 , 157, 657-664	10
120	The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer. 2018 , 17, 27	19
119	Synthesis of 2-alkylthio--(quinazolin-2-yl)benzenesulfonamide derivatives: anticancer activity, QSAR studies, and metabolic stability. 2018 , 149, 1885-1898	1
118	Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors. 2018 , 19,	27
117	Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. 2018 , 13, e0198141	11
116	Utilizing gastric cancer organoids to assess tumor biology and personalize medicine. 2019 , 11, 509-517	12
115	Targeted therapeutic options and future perspectives for HER2-positive breast cancer. 2019 , 4, 34	125
114	Exploring structural features of EGFR-HER2 dual inhibitors as anti-cancer agents using G-QSAR approach. 2019 , 39, 243-252	0
113	Design, synthesis, and biological study of 4-[(2-nitroimidazole-1-alkyloxy)aniline]-quinazolines as EGFR inhibitors exerting cytotoxicities both under normoxia and hypoxia. 2019 , 13, 3079-3089	4
112	The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. 2019 , 7, 1-32	9
111	Personalized medicine in breast cancer: pharmacogenomics approaches. 2019 , 12, 59-73	24
110	Validated liquid chromatography tandem mass spectrometry for simultaneous quantification of foretinib and lapatinib, and application to metabolic stability investigation.. 2019 , 9, 19325-19332	5
109	Protonation of Tyrosine Kinase Inhibitor Lapatinib: A Theoretical and Experimental Study. 2019 , 800, 19-24	

108	Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy. 2019 , 176, 393-409	6
107	Prolactin Disorders. 2019 ,	
106	STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. 2019 , 38, 195	142
105	Aggressive Prolactin-Secreting Pituitary Adenomas and Carcinomas. 2019 , 219-236	
104	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. 2019 , 139, 53-66	68
103	Drug sensitivity prediction with high-dimensional mixture regression. 2019 , 14, e0212108	7
102	Cytotoxic Effect of Paclitaxel and Lapatinib -Delivered in Polylactide--Poly(ethylene glycol) Micelles on HER-2-Negative Breast Cancer Cells. 2019 , 11,	16
101	Clinical development of targeted and immune based anti-cancer therapies. 2019 , 38, 156	93
100	(-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo. 2019 , 11,	16
99	Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. 2019 , 11,	75
98	The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid. 2020 , 38, 574-583	7
97	HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis. 2020 , 20, 47-56	6
96	Chemometrics-assisted development of a liquid chromatography method for estimation of lapatinib in tablets: A case study on a novel quality concept. 2020 , 3, 12-21	3
95	Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2. 2020 , 34, 293-303	4
94	Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway. 2020 , 531, 364-371	5
93	Protein Binding of Lapatinib and Its N- and O-Dealkylated Metabolites Interrogated by Fluorescence, Ultrafast Spectroscopy and Molecular Dynamics Simulations. 2020 , 11, 576495	3
92	DRIM: A Web-Based System for Investigating Drug Response at the Molecular Level by Condition-Specific Multi-Omics Data Integration. 2020 , 11, 564792	4
91	Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells. 2020 , 11, 944	3

90	An overview on precision therapy in bladder cancer. 2020 , 5, 347-361	
89	Short communication for targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches- part 2. 2020 , 87, 107242	3
88	Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells. 2020 , 28, 1375-1386	4
87	GalaxySagittarius: Structure- and Similarity-Based Prediction of Protein Targets for Druglike Compounds. 2020 , 60, 3246-3254	9
86	Monitoring the Crosstalk Between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 with PET. 2020 , 22, 1218-1225	1
85	-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy. 2020 , 9,	10
84	Development of innovative artificial neural networks for simultaneous determination of lapatinib and foretinib in human urine by micellar enhanced synchronous spectrofluorimetry. 2020 , 238, 118438	2
83	Structure-based virtual screening, pharmacokinetic prediction, molecular dynamics studies for the identification of novel EGFR inhibitors in breast cancer. 2021 , 39, 4462-4471	2
82	Gut Microbiome Critically Impacts PCB-induced Changes in Metabolic Fingerprints and the Hepatic Transcriptome in Mice. 2020 , 177, 168-187	12
81	Characterization of Locally Excited and Charge-Transfer States of the Anticancer Drug Lapatinib by Ultrafast Spectroscopy and Computational Studies. 2020 , 26, 15922-15930	4
80	Potential tripeptides against the tyrosine kinase domain of human epidermal growth factor receptor (HER) 2 through computational and kinase assay approaches. 2020 , 97, 107564	3
79	Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine. 2020 , 11, 3327-3333	2
78	Arsenic-induced HER2 promotes proliferation, migration and angiogenesis of bladder epithelial cells via activation of multiple signaling pathways in vitro and in vivo. 2021 , 753, 141962	7
77	Identification of a dual TAOK1 and MAP4K5 inhibitor using a structure-based virtual screening approach. 2021 , 36, 98-108	3
76	In vitro assessment of the photo(geno)toxicity associated with Lapatinib, a Tyrosine Kinase inhibitor. 2021 , 95, 169-178	6
75	Development of a Pediatric Mini-Tablet Formulation for Expedited Preclinical Studies. 2021 , 22, 40	0
74	Synthesis and Biological Evaluation of Novel 4-(4-Formamidophenylamino)--methylpicolinamide Derivatives as Potential Antitumor Agents. 2021 , 26,	
73	Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. 2021 , 144, 351-359	

72	Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach. 2021 , 11, 4495	14
71	Differential effects of epidermal growth factor receptor inhibitors in a single patient with neuropathic pain. 2021 , 14,	
70	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. 2021 , 214, 113218	22
69	Structural Insight of the Anticancer Properties of Doxazosin on Overexpressing EGFR/HER2 Cell Lines.	1
68	The Dynamic Interaction between Extracellular Matrix Remodeling and Breast Tumor Progression. 2021 , 10,	4
67	Biological Treatments of Neurofibromatosis Type 2 and Other Skull Base Disorders. 2021 , 54, 789-801	0
66	Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2. 2021 , 14,	4
65	miR-221 confers lapatinib resistance by negatively regulating p27 in HER2-positive breast cancer. 2021 , 112, 4234-4245	5
64	Topomer-CoMFA proposed as a tool to construct dual EGFR/HER-2 models. 2021 , 27, 239	
63	In vitro Evaluation of Isatin derivatives as Potent Anti-Breast Cancer Agents against MCF-7, MDA MB 231, MDA-MB 435 and MDA-MB 468 Breast Cancers cell lines: A Review. 2021 ,	2
62	Two Birds with a Stone: Molecular Cancer Therapy Targeting Signal Transduction and DNA Repair Pathways. 2013 , 163-186	1
61	Lapatinib. 2010 , 184, 45-59	6
60	HER2-positive DTCs/CTCs in breast cancer. 2012 , 195, 203-15	17
59	HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis. 2020 , 2, vdaa136	1
58	Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report. 2020 , 99, e23406	2
57	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. 2020 , 130, 4871-4887	15
56	ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. 2016 , 23, T243-T257	30
55	Anti-Neoplastic Cytotoxicity of Gemcitabine-(C)-[anti-EGFR] in Dual-combination with Epirubicin-(C)-[anti-HER2/] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole. 2014 , 2,	1

54	HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E. 2017 , 8, 19843-19854	30
53	The impact of systemic precision medicine and immunotherapy treatments on brain metastases. 2019 , 10, 6739-6753	4
52	The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. 2016 , 7, 2921-35	17
51	Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. 2016 , 7, 9135-49	27
50	Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. 2016 , 7, 33316-30	25
49	A Validated RP-HPLC Method for the Estimation of Lapatinib in Tablet Dosage form using Gemcitabine Hydrochloride as an Internal Standard. 2012 , 74, 580-3	8
48	Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine. 2015 , 6, 62-89	2
47	Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment. 2010 , 154, 281-8	16
46	Molecular docking studies shows tivozanib and lapatinib as potential inhibitors of EML4-ALK translocation mediated fusion protein in non small cell lung cancer. 2014 , 10, 658-63	2
45	Drug Combinations as a Therapeutic Approach for mTORC1 Inhibitors in Human Cancer. 2009 , 149-178	
44	Lapatinib. 2009 , 31,	
43	Comment augmenter la performance des médicaments anti-HER?. 2012 , 529-551	
42	Predicting Cancer Drug Response Using a Recommender System.	0
41	High-resolution mapping of cancer cell networks using co-functional interactions.	1
40	Metastatik meme kanseri tedavisinde lapatinib kapesitabin kombinasyonun etkinliđinin retrospektif deđlendirilmesi..	
39	Development and Application of Patient-Derived Cancer Organoids in Clinical Management of Gastrointestinal Cancer: A State-of-the-Art Review. 2021 , 11, 716339	0
38	Synergistic Effects of Metformin-Lapatinib Combination on the Expression of Bax in SK-BR3 Cells. 2020 , 11,	
37	Vaccines as Immunotherapy. 2021 , 31-61	0

36	Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors. 2021 , 17, 1311-1325	1
35	Brain-Restricted mTOR Inhibition with Binary Pharmacology.	1
34	Lapatinib'in sEn over ve uterus dokularMerine olan etkilerinin ¼ ve elektron mikroskopik d¼eyde ara¼tmas¼2020, 45, 921-932	1
33	Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. 2010 , 2, 13-25	15
32	First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.. 2022 , 1	0
31	2-substituted 4-aminoquinazoline derivatives as potential dual inhibitors of EGFR and HER2: an in silico and in vitro study. 1	0
30	Novel tryptanthrin hybrids bearing aminothiazoles as potential EGFR inhibitors: Design, synthesis, biological screening, molecular docking studies, and ADME /T predictions.	1
29	Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance.. 2022 , 13, 838171	1
28	Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review.. 2021 , 11,	3
27	Image_1.tiff. 2020 ,	
26	Image_2.tiff. 2020 ,	
25	Image_3.tiff. 2020 ,	
24	DataSheet1_v1.pdf. 2020 ,	
23	Binding Sites of Anticancer Drugs on Human Serum Albumin (HSA): A Review.. 2022 ,	
22	Paclitaxel and Lapatinib dual loaded chitosan-coated PLGA nanoparticles enhance cytotoxicity by circumventing MDR1-mediated trastuzumab resistance in HER2 positive breast cancers: In-vitro and in-vivo studies. 2022 , 103445	0
21	MAVEN: An R/Shiny app for compound mechanism of action analysis and visualisation using transcriptomics and compound structure data.	
20	An Overview of Breast Cancer Therapy. 2022 , 242-258	
19	Lapatinib- and fulvestrant-PAMAM dendrimer conjugates promote apoptosis in chemotherapy-induced senescent breast cancer cells with different receptor status. 2022 , 213047	2

18	Synthesis and in vitro anticancer activity of 4H-pyrano[2,3-d]pyrimidine-H-1,2,3-triazole hybrid compounds bearing D-glucose moiety with dual EGFR/HER2 inhibitory activity and induced fit docking study. 2022 , 133932	0
17	Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors. 2022 , 128, 106099	0
16	Brain-restricted mTOR inhibition with binary pharmacology. 2022 , 609, 822-828	1
15	Signaling pathways and therapeutic interventions in gastric cancer. 2022 , 7,	0
14	FDA approved six-membered ring fused pyrimidine-based derivatives. 2023 , 221-248	0
13	Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. 2022 , 13, 2065	1
12	Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment. 2022 , 15, 1452	0
11	Sanyin Formula Enhances the Therapeutic Efficacy of Paclitaxel in Triple-Negative Breast Cancer Metastases through the JAK/STAT3 Pathway in Mice. 2023 , 16, 9	0
10	Are chemical compounds in medical mushrooms potent against colorectal cancer carcinogenesis and antimicrobial growth?. 2022 , 22,	0
9	Synthesis of New Bioactive Indolyl-1,2,4-Triazole Hybrids As Dual Inhibitors for EGFR/PARP-1 Targeting Breast and Liver Cancer Cells. 2022 , 7, 45665-45677	0
8	Lapatinib: A comprehensive profile. 2022 ,	0
7	The impact of violating the independence assumption in meta-analysis on biomarker discovery. 13,	0
6	Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy.	0
5	Anti-EGFR Therapy in Gallbladder Cancer. 2023 , 331-349	0
4	Targeting synthetic lethal paralogs in cancer. 2023 ,	0
3	Complex formulation strategies to overcome the delivery hurdles of lapatinib in metastatic breast cancer. 2023 , 82, 104315	0
2	Detailed curriculum vitae of HER2-targeted therapy. 2023 , 245, 108417	0
1	Targeted therapy. 2023 , 205-411	0

